search icon
search icon
Flag Arrow Down
Română
Română
Magyar
Magyar
English
English
Français
Français
Deutsch
Deutsch
Italiano
Italiano
Español
Español
Русский
Русский
日本語
日本語
中国人
中国人

Change Language

arrow down
  • Română
    Română
  • Magyar
    Magyar
  • English
    English
  • Français
    Français
  • Deutsch
    Deutsch
  • Italiano
    Italiano
  • Español
    Español
  • Русский
    Русский
  • 日本語
    日本語
  • 中国人
    中国人
Sections
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
About Us
Contact
Privacy policy
Terms and conditions
Quickly scroll through news digests and see how they are covered in different publications!
  • News
  • Exclusive
    • INSCOP Surveys
    • Podcast
    • EU
    • Diaspora
    • Republic of Moldova
    • Politics
    • Economy
    • Current Affairs
    • International
    • Sport
    • Health
    • Education
    • IT&C knowledge
    • Arts & Lifestyle
    • Opinions
    • Elections 2025
    • Environment
134 new news items in the last 24 hours
  1. Home
  2. International

Moderna and Merck announce promising results for the personalized vaccine against melanoma recurrence

Matei Gaginsky
whatsapp
facebook
linkedin
x
copy-link copy-link
23 October 2026, 18:49
main event image
Health
Foto: Shutterstock.com
google-preference

Always see our news on Google

Moderna and Merck have announced promising final clinical results for a personalized messenger RNA-based therapeutic vaccine administered after the surgical removal of melanoma. Combined with existing immunotherapy, the therapy reduced the risk of recurrence or death by more than 40% among patients enrolled in advanced clinical trials.

The vaccine is created individually for each patient. After surgery, the tumor tissue is genetically sequenced to identify mutations specific to cancer cells. Based on this information, a personalized injection is produced to train the immune system to recognize and destroy any malignant cells that may remain in the body.

The results represent an important advance in immuno-oncology and support expanding research to other forms of cancer, including lung cancer. The approach differs from standard treatments because it aims to adapt therapy to the genetic profile of each tumor.

Widespread implementation remains difficult, however. Individualized production, genetic sequencing, and the time required to manufacture each dose may generate high costs and logistical challenges for public healthcare systems. Companies and researchers must continue to confirm the therapy’s efficacy and safety before it can be used more broadly.

Sources

sursa imagine
Newsweek
Revoluție în Oncologie. Vaccinul personalizat pe ARN mesager reduce riscul de recidivă cu peste 40% * Newsweek România
sursa imagine
Hot News
Un nou vaccin reduce cu 42% riscul de deces sau de recidivă în cazul uneia dintre cele mai agresive forme de cancer, arată studiile
sursa imagine
G4Media
Merck și Moderna anunță că vaccinul lor împotriva cancerului reduce cu 42% riscul de deces sau de recidivă în cazul melanomului
sursa imagine
Agerpres
Vaccinul Merck/Moderna împotriva cancerului reduce cu 42% riscul de deces sau de recidivă în cazul melanomului

Latest News

23:52

Ilie Bolojan announces that the PNL and USR have finalized the proposal to reduce the number of parliamentarians: “Now we no longer have any constraints”

23:34

Donald Trump asks Nvidia to give Jensen Huang a “second chance”

23:17

ECB reorganizes its leadership in 2027 / Spain is expected to take over the institution’s presidency, while France and Germany propose candidates for key positions

22:59

Ilie Bolojan criticizes the administrative reorganization of the Government formed mostly of PSD members: “There is nothing serious”

22:43

A delivery driver from Sri Lanka attacked in Iași County. The attacker destroyed his scooter and phone

See more news

NEWS ON THE SAME TOPICS

event image
International
Russia will use the CaTeVac vaccine from 2027 to treat sarcomas
event image
Health
The pharmaceutical group Minapharm will develop a candidate vaccine against the Bundibugyo Ebola strain, with funding of 16.5 million dollars.
event image
Health
The U.S. Food and Drug Administration has approved a drug that doubles the survival rate of patients with advanced pancreatic cancer.
event image
EU
The EU–Africa Partnership is providing more than €64 million to fund five networks aimed at speeding up clinical trials during epidemics
event image
Health
Alexandru Rogobete proposes expanding genetic testing to six types of cancer, with reimbursement expected from January 1, 2027
event image
Health
Interferon alfa-2b returns to stock at the Oncology Institute
app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview app preview
modern Merck oncology Vaccine melanoma

Editor’s Recommendations

main event image
Current Affairs
4 hours ago

EUROCONTROL blocks the sums owed to ROMATSA again / The garnishment was imposed at Pfizer’s request in the dispute concerning COVID-19 vaccines

Sources
imagine sursa
imagine sursa
imagine sursa
imagine sursa
main event image
Exclusive
14 hours ago

EXCLUSIVE | Romania, as viewed by the Russian press / The scenario of unification with the Republic of Moldova, described as a “capitulation” of Chișinău

main event image
Opinions
9 hours ago

Andrei Cornea: Politics, Ethics and Fanaticism

app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview
app store badge google play badge
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
  • About Us
  • Contact
Privacy policy
Cookies Policy
Terms and conditions
Open source licenses
All rights reserved Strategic Media Team SRL

Technology in partnership with

anpc-sal anpc-sol